Rhythm Pharmaceuticals Inc to Discuss Preliminary Data from Exploratory Phase 2 PWS Trial Transcript
Ladies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceuticals conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.
Please be advised that today's conference is being recorded. I would like now to turn the conference over to Dave Connolly, head of investor relations. Please go ahead.
Thank you, Michelle.
Good morning, everyone, and welcome. This morning we issued a press release announcing that the preliminary data from our exploratory phase 2 trial showed sent melanoide demonstrated a positive efficacy signal in Prader-Willi syndrome. You can access the press release as well as the slides that we will be reviewing today by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
